Clomiphene Citrate Induces ROS-Mediated Apoptosis in Mammalian Oocytes

Shail K. Chaube1*, Tulsidas G. Shrivastav2, Shilpa Prasad1, Meenakshi Tiwari1, Anima Tripathi1, Ashutosh N. Pandey1, Karuppanan V. Premkumar1

1Cell Physiology Laboratory, Biochemistry Unit, Department of Zoology, Banaras Hindu University, Varanasi-221005, India
2Department of Reproductive Biomedicine, National Institute of Health and Family Welfare, New Delhi-110067, India

Email: *shailchaubey@gmail.com

Received 27 May 2014; revised 28 June 2014; accepted 16 July 2014

Copyright © 2014 by authors and Scientific Research Publishing Inc.
This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/

Abstract

The clomiphene citrate (CC), a nonsteroidal triphenylethylene compound, is a first line of medicine used for the induction of ovulation in anovulatory women worldwide. In spite of high ovulation induction with the use of CC, the pregnancy rate is much lower. Such a discrepancy could be due to the peripheral anti-estrogenic effect of CC, particularly at the level of ovary, endometrium and cervical mucus. CC induces ovulation by binding to the estrogen receptors and generates hypoestrogenic state in hypothalamus leading to release of pituitary gonadotropins. CC may have a direct effect at the level of ovary but the molecular mechanism remains unclear. Animal studies suggest that the CC induces apoptosis in granulosa cells and results hypoestrogenic state in the ovary. Reduced estradiol 17β level in the ovary affects development and maturation of oocyte leading to oocyte apoptosis. Further, CC increases hydrogen peroxide (H2O2) level and thereby bax protein expression and DNA fragmentation in cumulus-granulosa cells as well as in oocytes. The exogenous supplementation of either estradiol 17β or melatonin reduces H2O2 level in ovary, delays meiotic cell cycle progression in oocyte and protects oocyte apoptosis. Hence, supplementation of estradiol 17β or melatonin along with CC could be beneficial to protect granulosa cell as well as oocyte apoptosis and inhibit deterioration of oocyte quality. Thus, maintenance of oocyte quality may overcome the adverse effect caused due to CC treatment during infertility management.

Keywords

Clomiphene Citrate, Ovulation Induction, ROS Generation, Apoptosis, Oocyte Quality

*Corresponding author.
1. Introduction

Ovary is a metabolically active organ that generates reactive oxygen species (ROS) on an extraordinary scale during final stages of folliculogenesis and ovulation. These increased levels of ROS are scavenged by enzymatic as well as non-enzymatic antioxidants [1]-[3]. Although generation of a tonic level of ROS is beneficial for meiotic maturation in rat oocytes [4]-[6], overproduction of ROS in the follicular fluid or depletion of antioxidant system leads to oxidative stress [1] that may affect oocyte quality and thereby ART outcome [7].

Ovulatory dysfunction is one of the most common causes of reproductive failure in sub-fertile and infertile women. The anovulatory infertility may be because of polycystic ovary syndrome (PCOS), obesity, hypothalamic dysfunction, stress, hyperprolactinemia, pituitary tumors or thyroid disease in human [8]. The unexplained infertility contributes to 20% - 25% of total infertility in female [9]. In the absence of other significant infertility factors in couples, successful ovulation induction often restores normal fertility in human [10].

The injectable gonadotropins or anti-estrogens including clomiphene citrate (CC) is used to stimulate ovary in infertile women [11]. Gonadotropin induces steroidogenesis in follicular cells by cyclic adenosine 3’,5’-cyclic monophosphate (cAMP)-mediated pathway and stimulates growth, development and maturation of mammalian ovarian follicles [12]-[14]. Further, studies in monkey as well as in cattle suggest that gonadotropins directly stimulate PGE2 synthesis in granulosa cells required for follicular rupture that results in ovulation [15]-[17]. However, exogenous gonadotropin therapy is an expensive treatment and also requires clinicians with requisite training and experience. CC is a very cheap and easily available drug and hence it is poor man’s medicine for the treatment of anovulatory dysfunction worldwide. More than 80% of women ovulate when they are treated with CC [9].

CC is the first line of medicine used for ovulation induction in anovulatory women worldwide [9]. CC is structurally similar to estrogen and thus it binds to estrogen receptors (ER) at the hypothalamic level as depletion of hypothalamic ER prevents correct analysis of circulating estrogen levels. Feedback due to this reduced estrogen level triggers hypothalamic gonadotropin-releasing hormone (GnRH) secretion. The increased GnRH secretion from hypothalamus stimulates the release of pituitary gonadotropins. Both luteinizing hormone (LH) as well as follicle stimulating hormone (FSH) surge finally triggers growth and development of ovarian follicles by inducing steroidogenesis [23]. In successful treatment cycle with CC one or more dominant follicle emerge, mature and finally gets ruptured that results in the ovulation of M-II arrested oocytes required for successful fertilization in various ART programs. However, CC treatment may be ineffective in women with hypogonadotropic hypogonadism as well as hypergonadotropic hypogonadism [9]. Although standard effective dose of CC ranges from 50 mg per day-250 mg per day, more than 100 mg per day is not permitted by US Food and Drug Administration [24]. The CC dose is increased from 50 mg to 100 mg and even more in patients who do not ovulate at standard effective dose of CC. However, ovulation rate decreases with the increasing dose of CC (22% with 100 mg, 12% with 150 mg, 7% with 200 mg and 5% with 250 mg per day) [25]. Higher doses of CC may trigger ovarian hyperstimulation and granulosa cell apoptosis in vitro. Clinically, multiple gestation, congenital anomalies and ovarian cancer occur with high dose of CC treatment [9] [26]. Although, CC has been used for ovulation induction worldwide, the possible molecular mechanisms of how CC works at the level of ovary remains ill understood.

3. Clomiphene Citrate-Induced Apoptosis

In spite of high ovulation induction with the use of CC (57% - 91%), the pregnancy rate (20% - 40%) is much
lower in humans [27]. Moreover, there is a higher than expected incidence of miscarriage in the conception cycle after CC treatment in humans [28]. Such a discrepancy is believed to be due to anti-estrogenic effect of CC, particularly at the level of ovary, cervical mucus and endometrium in human [25] [29]-[31]. The anti-estrogenic effects of CC may affect final stages of folliculogenesis by inducing apoptosis in encircling granulosa cells and oocyte in ovary in vitro. This was further strengthened by animal studies that CC treatment induced granulosa cell as well as oocyte apoptosis in rats in vivo [32]. However, there is no evidence to support this possibility in human.

The anti-estrogenic effects of CC and the mechanism by which CC exerts its direct action at the level of ovary remains poorly understood. One study suggest that CC induces apoptosis in human granulosa cells cultured in vitro [26] and reduces estradiol 17β as well as progesterone synthesis in rat [33] and in humans [26] [34]. These finding were further supported by animal studies that CC induces granulosa cell apoptosis and reduced level of estradiol 17β in ovary as well as circulation in rat [32] [35] as well as in monkey [36]. Studies carried out in humans as well as in animal model suggest that CC induces granulosa cell apoptosis, which are the main source of estradiol 17β biosynthesis. The decreased number of the active granulosa cells could be one of the causes for the reduction of estradiol 17β level in ovary as well as circulation.

The developed hypoestrogenic condition after CC treatment may induce generation of ROS and thereby deterioration of oocyte quality by inducing apoptosis. This possibility was further strengthened by observations that CC treatment increased hydrogen peroxide (H2O2) level and reduced catalase activity in ovary. The increased level of H2O2 induced bax protein expression and DNA fragmentation both in cumulus-granulosa cells and oocytes in rat as well as in human [32] [35]. Further, CC induced atretic like changes in preovulatory follicles [37], induced oocyte degeneration and reduced fertilization [38] [39]. Based on these studies, we propose that CC induces generation of ROS and thereby apoptosis in granulosa cells. Granulosa cell apoptosis further reduces estradiol 17β level in ovary as well as in circulation. The reduced level of estradiol 17β in ovary may affect the achievement of meiotic competency of follicular oocytes. After ovulation, these oocytes become more susceptible towards apoptosis, which results in the deterioration of oocyte quality and poor assisted reproductive technology (ART) outcome.

4. Protection of Clomiphene Citrate-Induced Apoptosis

The hypoestrogenic condition due to CC treatment affects the development and maturation of oocytes in the ovary and reduces oocyte quality after ovulation. The increased estradiol 17β even at supraphysiological level (3000 pg/mL of serum) does not affect the oocyte and embryo quality in the oocyte donation cycle of human [40]. Hence, a possibility exists that the exogenous supplementation of estradiol 17β may prevent CC-induced hypoestrogenic condition. This possibility was further supported by data obtained through animal studies in rat model that the exogenous supplementation of estradiol 17β compensates CC induced hypoestrogenic condition and maintains granulosa cell survival inside follicular microenvironment [33]. The increased growth and survival factor due to exogenous supplementation of estradiol 17β protects deterioration of oocyte quality [32] [33]. The use of exogenous estradiol 17β has been recommended after the completion of CC regimen in humans, and clinical studies have supported the beneficial effects of exogenous estradiol 17β in patients [41]-[45]. Hence, the use of exogenous estradiol 17β can overcomes the side effects of CC during ovulation induction in humans (Figure 1).

CC induces generation of ROS and apoptosis in cancer cells [46]. Animal studies suggest that CC induces accumulation of ROS in ovary possibly by inhibiting catalase activity leading to oocyte apoptosis in rat [35]. Therefore, the use of natural antioxidant could be better over estradiol 17β supplementation in terms of preventing CC-induced adverse effects at the level of ovary. Melatonin is a natural antioxidant which scavenges free radicals [47] and also induces antioxidant enzymes such as superoxide dismutase [48] [49] and glutathion peroxidase activities preventing oxidative damage in human [50] [51]. Previous studies suggest that melatonin supplementation protects oocytes from free radical damage, improving fertilization rate in rat, goat, porcine, ewes, ovine and human [7] [52]-[57] and inducing embryo viability in ewes [58]. Recently, it has been reported in rat oocytes that melatonin reduces H2O2 level by increasing catalase activity and protects against CC-induced oocyte apoptosis [35]. Further, melatonin slows down meiotic cell cycle progression since antral follicles had germinal vesicle stage oocytes and extrusion of first polar body was still in progress even after ovulation [35]. Thus, supplementation of melatonin could be beneficial to protect CC-induced generation of ROS and thereby
apoptosis in mammalian ovary (Figure 1).

5. Summary

The molecular mechanism by which CC induces apoptosis at the level of ovary remains poorly understood in human. Based on the animal studies, we propose that CC induces generation of ROS and thereby apoptosis in granulosa cells that are responsible for estradiol 17β synthesis. The granulosa cell apoptosis also reduces granulosa cells-oocyte communication by disrupting gap junctions. The disruption of gap junction affects the supply of nutrients and maturation enabling factors that are required for the achievement of meiotic competency of preovulatory oocytes. As a result, oocyte becomes more susceptible towards apoptosis that leads to deterioration of oocyte quality after ovulation leading to poor ART outcome. Thus, based on the animal studies, we suggest the use of either estradiol 17β or melatonin along with CC to overcome the discrepancies rises due to adverse effects caused by CC at the level of ovary during infertility management in human.

Conflict of Interest

The authors declare no conflict of interest.

References


S. K. Chaube et al.


Scientific Research Publishing (SCIRP) is one of the largest Open Access journal publishers. It is currently publishing more than 200 open access, online, peer-reviewed journals covering a wide range of academic disciplines. SCIRP serves the worldwide academic communities and contributes to the progress and application of science with its publication.

Other selected journals from SCIRP are listed as below. Submit your manuscript to us via either submit@scirp.org or Online Submission Portal.